Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus DITROPAN XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus DITROPAN XL.
DETROL LA vs DITROPAN XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Oxybutynin is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing detrusor muscle contraction and bladder smooth muscle spasm, thereby increasing bladder capacity and decreasing urge incontinence.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
Oral: 5 to 10 mg once daily; maximum 30 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
The terminal elimination half-life of oxybutynin is approximately 12-13 hours for the immediate-release formulation, but for DITROPAN XL, due to its extended-release profile, the effective half-life is extended, allowing once-daily dosing. Clinical context: steady-state is achieved within 3 days of dosing.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Approximately 50% of the administered dose is excreted in urine as unchanged drug and its active metabolite, N-desethyloxybutynin, with the remainder excreted in feces via biliary elimination.
Category C
Category C
Anticholinergic
Anticholinergic